BrainsWay Ltd. (NASDAQ:BWAY) Short Interest Up 5.3% in July

BrainsWay Ltd. (NASDAQ:BWAY) saw a large growth in short interest in July. As of July 31st, there was short interest totalling 41,400 shares, a growth of 5.3% from the July 15th total of 39,300 shares. Based on an average daily volume of 70,000 shares, the short-interest ratio is presently 0.6 days.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on BWAY. Oppenheimer lifted their price target on BrainsWay from $10.00 to $11.00 and gave the company an “outperform” rating in a report on Thursday, May 9th. HC Wainwright lifted their price target on BrainsWay from $15.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Finally, Northland Securities lifted their price target on BrainsWay from $9.00 to $11.00 and gave the company an “outperform” rating in a report on Wednesday, August 7th.

BrainsWay Price Performance

Shares of BrainsWay stock traded up $0.07 during midday trading on Friday, reaching $7.87. The company had a trading volume of 157,885 shares, compared to its average volume of 95,233. The firm has a market cap of $131.15 million, a PE ratio of -87.44 and a beta of 1.24. The stock has a fifty day moving average price of $6.62 and a 200 day moving average price of $6.07. BrainsWay has a fifty-two week low of $2.94 and a fifty-two week high of $8.28.

BrainsWay (NASDAQ:BWAY) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.04 EPS for the quarter. The firm had revenue of $10.01 million during the quarter, compared to analysts’ expectations of $9.40 million. BrainsWay had a negative return on equity of 3.98% and a negative net margin of 4.83%. During the same quarter last year, the firm posted ($0.05) earnings per share. As a group, sell-side analysts forecast that BrainsWay will post 0.02 EPS for the current year.

Hedge Funds Weigh In On BrainsWay

A number of large investors have recently made changes to their positions in BWAY. Jump Financial LLC bought a new position in BrainsWay in the 4th quarter worth about $207,000. Acadian Asset Management LLC lifted its position in BrainsWay by 583.2% during the first quarter. Acadian Asset Management LLC now owns 175,416 shares of the company’s stock valued at $923,000 after purchasing an additional 149,740 shares during the last quarter. Quadrature Capital Ltd purchased a new position in BrainsWay in the 4th quarter worth approximately $70,000. Virtu Financial LLC bought a new position in shares of BrainsWay in the 1st quarter worth $60,000. Finally, Essex Investment Management Co. LLC purchased a new stake in shares of BrainsWay during the 4th quarter valued at $1,531,000. 30.11% of the stock is owned by institutional investors.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.